---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-241867"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2026-05-27T20:05:16+00:00"
generated_at: "2026-05-27T20:08:19.771154+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aptevo (APVO) partners with Niowave for radiopharma development; Niowave takes 7.9% equity stake

## Summary
- 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs using Aptevo's multispecific platforms and Niowave's radioisotopes.
- Niowave made initial $500K equity investment for 7.9% stake; potential up to 19.99% through warrant exercises at $8.00/share.
- First program targets Nectin-4 with Actinium-225; proof-of-concept study to begin.
- Deal marks Aptevo's expansion into radiopharmaceuticals; Niowave's first therapeutic development investment.
- Niowave to supply radioisotopes if it opts out of collaboration; Aptevo retains development rights.

## SEC filing metadata
- accession: 0001193125-26-241867
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2026-05-27T20:05:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312526241867/0001193125-26-241867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312526241867/apvo-20260525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-241867
- JSON: https://secwatch.observer/filing/0001193125-26-241867.json
- Plain text: https://secwatch.observer/filing/0001193125-26-241867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.